Search PubMed⌕ Search

Biomedical subjects

D Vergoz

Publications and source records attributed to D Vergoz.

At least 55 records · Page 3Linked to original sources
PubMedDate not supplied

[Fibrinolytics and defibrinating agents].

Therapeutic fibrinolysis represents the only logical means of curing thromboses, by assuring the destruction of the thrombus. This kind of therapy, which was introduced clincally over 10 years ago, has been used on only a limited scale because of the high risk of haemorrhage and the need for highly specialized laboratory control tests. Different methods of administration, overcoming one or other of these disadvantages, have resulted recently in its wider use but this has been accompanied by a reduction in efficacity. The very satisfactory clinical results obtained in some cases remain limited and thus in this context the indications should not be restricted.

Batroxobin↗
PubMedDate not supplied

[Hemostatic pastes].

Explore the source record for details and available documents.

Dental Care for Persons with Disabilities↗
PubMedDate not supplied

[Antithrombin III deficiency induced by heparin and constitutional protein C deficiency. Apropos of a case].

Major mesenteric venous thrombosis in a young man who had already had spontaneous thromboembolic accidents prompted the diagnosis in 1982 of 'Antithromin III' deficiency. The initial reduction of this inhibitor proved to be secondary to a consumption raised abnormally by Heparin. Research into the family antecedents made it possible in 1983 to discover a constitutional 'Protein C' deficiency without stopping the antivitamins K for this patient.

Adult↗
PubMedDate not supplied

[A case of dysfibrinogenemia complicated by hemorrhage and thrombosis].

There are, as well as the more common coagulopathies such as deficiency in antithrombin III or Protein C, certain rare disorders complicated simultaneously by haemorrhage and thrombosis--such as dysfibrinogenemia--which can present very special therapeutic problems.

Afibrinogenemia↗
PubMedDate not supplied

[Physiopathology of hemostasis. Which advances are useful for the clinician?].

Progress made in the field of haemostasis 30 years ago was essentially to do with the identification of the different activators of coagulation, the deficits of which provoke hemorrhage. Over the last ten years, progress has been made which is of benefit to research into thrombosis. This wave of progress, still in its infancy, aids both the understanding of the mechanisms involved, and the treatment of thrombosis. The role of the deficits reducing coagulation in the occurrence of thromboses is the most distinctive if not unique, fact. The molecular study of the factors of coagulation constitutes another aspect of recent progress; this gives a better understanding of the pathological phenomena and anticoagulant behaviour. Examples are given of this progress in molecular study and in the aetiological diagnosis of thrombosis.

Antithrombin III↗
PubMedDate not supplied

[Clinical problems posed by the consumption of antithrombin III induced by heparin].

Two cases of resistance to the heparin treatment, induced by large consumption of antithrombin III, are reported. Normally small, this consumption does not automatically call for the systematic dosage of Antithrombin III for each treatment using heparin. On the other hand, any clinical or biological resistance to higher doses of heparin, any personal or family history of thrombosis necessitate the administration of Antithrombin III. Where there is an acquired or congenital deficit, an injection of Antithrombin III corrects the disorder and reduces the risk of thrombosis. In the case of a heparin-antivitamin K relay, it is essential to achieve complete biological effectiveness of the antivitamins K to interrupt the administration of the heparin.

Adult↗